SAN FRANCISCO–(BUSINESS WIRE)–#DIMERx—DIMERx, a leading pioneer of covalent chemistry-based dimer technology, is pleased to announce the appointment of two influential individuals to its Board of Directors: Peter Barton Hutt and Harvinder Dhani. These appointments represent a significant step in furthering the company’s commitment to innovative small molecule treatment modalities for underserved patients.
Peter Barton Hutt brings with him a wealth of complex regulatory and pharmaceutical experience amassed over career-spanning decades. He is a senior counsel in the Washington, DC law firm of Covington & Burling LLP. Except for his 4 years in the government, Mr. Hutt has continued at the firm for most of his career. As the chief counsel at the FDA during 1971-1975, he transformed the Agency from outdated law enforcement to modern administrative law. Outside the government, he drafted the legislation that led to creation of National Institute of Alcohol Abuse and Addiction and National Institute of Drug Addiction. He continues to serve on a wide variety of other academic and scientific Advisory Boards, on the Board of Directors of venture capital startup companies, and on the Advisory Boards of venture capital firms.
“I am honored to be on the DIMERx Board. While the U.S. is making progress on harm reduction strategies, we should also continue to leverage every avenue possible to develop non-addictive analgesics as the first-line therapy and minimize our reliance on addictive opioids as the standard of care for management of pain,” stated Mr. Hutt. “I believe DIMERx is on the right track and has a promising lead candidate which has the potential to treat pain without the risk of addiction associated with conventional opioids.”
Harvinder Dhani brings a wealth of expertise as a seasoned health tech investor with a deep commitment to societal altruism that aligns perfectly with DIMERx’s mission to improve healthcare outcomes. Mr. Dhani’s distinguished career in the healthcare technology sector spans over two decades, during which he has demonstrated an unwavering dedication to advancing healthcare solutions that benefit not only patients but also society as a whole. His vision for ethical, patient-centric healthcare innovation and his track record of successful investments make him a valuable resource to the DIMERx leadership team.
“Coming from Indiana, I am familiar with the damage done by the opioid epidemic. If anything, Midwest communities were the first to fall victim to this malaise,” Mr. Dhani said. “In DIMERx, I saw a vision and passion to address this epidemic head-on through developing a non-addictive pain drug. I am humbled that DIMERx has asked me to join the Board and I want to see the company succeed.”
“We are very thrilled to welcome Peter Barton Hutt and Harvinder Dhani to our Board of Directors,” said Nikhilesh Singh, Ph.D., Co-Founder and Chief Executive Officer. “Their expansive knowledge and diverse perspectives will be instrumental in shaping our strategic direction and driving our commitment to patients. Both Mr. Hutt and Mr. Dhani bring a wealth of experience and shared dedication to advancing healthcare. Their appointments reflect DIMERx’s ongoing commitment to fostering innovation while ensuring the best interests of patients and stakeholders.”
About DIMERx, Inc.
DIMERx is a clinical-stage biopharmaceutical company focused on the development of innovative and de-risked first-in-class dimer therapeutics. Leveraging its proprietary dimer platform technology engineered by founder Nikhilesh Singh, Ph.D., DIMERx is advancing DMX-101 and a pipeline of additional dimer conjugates. DIMERx is currently raising Series A financing to see DMX-101 through clinical proof of concept for chronic pain and advance at least one additional dimer to the point of filing an Investigational New Drug submission with the FDA. DMX-101 is also Phase 2b/3a ready for chronic treatment of IBS-D in patients with and without gallbladder.
This press release contains “forward-looking statements,” which reflect our current views and expectations with respect to future outcomes or events. When used in this press release, the words “could,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project” and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. Because these statements are based on current estimates and assumptions, they are inherently subject to risks that could cause the actual outcomes to differ materially from what we currently expect. These forward-looking statements are subject to numerous risks and uncertainties, including, among others, the facts that we are substantially dependent on our ability to successfully develop and commercialize our products; the commercial adoption of our products and any other product candidates we develop will depend on the degree of their market acceptance; we have only limited assets and will need to raise additional capital before we can expect to generate revenue or become profitable; and we have never generated any revenue and may never be profitable. Forward-looking statements in this presentation apply only as of the date made, and we undertake no obligation to update or revise any forward-looking statements to reflect subsequent events or circumstances.